Webinar: CHA™ Life Sciences Consulting: Leveraging Our Scientific Expertise to Improve Your Bottom LineIn this webinar, learn how Cambridge Healthtech Associates™ (CHA™) works with clients on business strategy, market research and product development. CHA General Manager, Dawn Van Dam, and Business Development Manager, Brian Murphy provided an overview, including case studies, on how we leverage specific scientific expertise and a deep understanding of the life sciences industry to help companies penetrate the marketplace. >>
Webinar: CHA Technology Evaluations in Life Sciences: Industry Collaboration Case Studies
In this webinar, CHA General Manager Dawn Van Dam and CHA Business Development Manager Brian Murphy discussed how CHA uses online communities to help clients increase brand awareness and effectively reach target audiences. >>
Webinar: CHA Online Communities
In this webinar, CHA General Manager Dawn Van Dam and CHA Business Development Manager Brian Murphy discussed how CHA uses online communities to help clients increase brand awareness and effectively reach target audiences. >>
Article: The Case for Investing in Predictive Safety Technologies
Although the differences between a discovery-stage efficacy test and a drug safety test are conceptually simple, entering the drug safety market requires more effort than breaking into the discovery market. >>
Article: Five Points to Consider Before Introducing a New Technology to the Preclinical Drug Safety Assessment Market
The successful commercialization of new predictive safety platforms is an incredibly challenging and resource-intensive process. These challenges are often exacerbated when new technology providers approach the market with products that have not been adequately qualified or scientifically validated; or worse, when the products are poorly positioned to meet the needs of the of the bio-pharma marketplace >>
On-Demand WebinarListen to the recording CHA's webinar entitled NGS Solutions: Managing Platforms and People to Maximize Productivity. Participants were George Grills (Cornell University), Richard Resnick (GenomeQuest), Matthew Trunnell (Broad Institute), Kevin Davies (Bio-IT World) >>
Article: Convincing Pharmaceutical Companies to Adopt Your Novel TechnologyThree Required Elements to Include in Your Qualification Documents It’s one of the most common questions asked by new technology providers and the response varies among biopharmaceutical companies as well as individuals within those companies. There is no industry standard for the minimum data requirement >>
Article: How Technology Providers Can Help Preclinical Safety Heads (by Ernie Bush)
Department heads in preclinical safety groups have the same headaches of budget, performance, and facilities management as every other functional leader, plus they have the added burden of ultimately advising on whether a compound is indeed ‘safe’ for administration to humans >>
Article: Top Excuses for Not Adopting a New Safety Evaluation Technology (By Ernie Bush)
In both my personal experience as a senior manager at large pharma for over 20 years, and in my role facilitating peer evaluations of new technologies at CHA for the past five years, I have noticed that there are a few reasons consistently offered for why a particular new technology for safety evaluation >>
PRESS RELEASES
Cambridge Healthtech Associates™ Announces Results of Survey on Trends in Safety Biomarkers (30 July 2012) Cambridge Healthtech Associates™ (CHA™) today announced results of industry survey of biotech and pharmaceutical companies on the use of safety biomarkersin the development of new medications. >>
Cambridge Healthtech Associates™ Announces arGEN-X as Inaugural Signature Award™ Winner (14 May 2012) Cambridge Healthtech Associates™ (CHA™) today announced that arGEN-X is the winner of its inaugural Signature Award™. >>
Cambridge Healthtech Associates™ and Nucro-Technics Announce New Market Investigation (5 April 2012) Cambridge Healthtech Associates™ (CHA™) and Nucro-Technics, a full-service Pharmaceutical Contract Support Organization, today announced a new partnership focused on a market evaluation of a new biomarker tool set to predict safety adverse events. >>
Cambridge Healthtech Associates™ Expands Consulting Services into Next-Generation Sequencing and Genomics (26 March 2012) Cambridge Healthtech Associates™ (CHA™) announces a new program of consulting and allied services dedicated to the next-generation sequencing and genomics field. >>
Cambridge Healthtech Associates™ Names Dawn Van Dam General Manager (19 December 2011) Cambridge Healthtech Associates™ (CHA™) announces the appointment of Dawn Van Dam as General Manager. >>
CHA and CYTOO Announce a Collaborative Technology Evaluation (27 April 2011) The Drug Safety Executive Council (DSEC), an industry membership run by CHA, together with CYTOO, a provider of innovative products for the life science research and drug discovery markets with an emphasis in cell-based assays, high-content analysis and cell screening >>
CHA and Metanomics Health GmbH Announce a Collaborative Technology Evaluation (7 April 2011) The Drug Safety Executive Council (DSEC), an industry membership run by CHA, together with Metanomics Health GmbH, a BASF Group company and leader in offering targeted and non-targeted metabolite profiling to healthcare customers, today announced a new project as part of DSEC's Technology Evaluation Consortium >>
Biocortech and DSEC Announce Technology Evaluation Consortium (17 June 2010) Biocortech, the biopharmaceutical company dedicated to the development of drug safety screening assays and in vitro blood tests for neuropsychiatric disorders, and DSEC ( Drug Safety Executive Council) today announced that they entered into a Technology Evaluation Consortium >>